Article Information
History
- February 18, 2021.
Article Versions
- Version 1 (December 22, 2020 - 09:14).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Cristina Venturini1,
- Charlotte J Houldcroft2,
- Arina Lazareva3,
- Fanny Wegner1,
- Sofia Morfopoulou1,
- Persis J. Amrolia3,
- Zainab Golwala4,
- Anupama Rao4,
- Stephen D. Marks5,6,
- Jacob Simmonds4,
- Tetsushi Yoshikawa7,
- Paul J. Farrell8,
- Jeffrey I. Cohen9,
- Austen J. Worth10 and
- Judith Breuer1,4,*
- 1Institute of Child Health, University College London, London, UK
- 2Department of Medicine, University of Cambridge, Cambridge, UK
- 3Bone Marrow Transplantation Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
- 4Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
- 5Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
- 6University College London Great Ormond Street Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK
- 7Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan
- 8Section of Virology, Department of Infectious Disease, Imperial College Faculty of Medicine, London, UK
- 9Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
- 10Department of Immunology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
- ↵*Corresponding author: Judith Breuer, Division of Institute Child Health, University College London, 30 Guilford St, Holborn, London WC1N 1EH. Contact email: j.breuer{at}ucl.ac.uk.
Posted February 18, 2021.
EBV deletions as biomarkers of response to treatment of Chronic Active Epstein Barr Virus
